AR122917A1 - ZIBOTENTAN AND DAPAGLIFLOZIN COMBINATION FOR THE TREATMENT OF ENDOTHELIN-RELATED DISEASES - Google Patents
ZIBOTENTAN AND DAPAGLIFLOZIN COMBINATION FOR THE TREATMENT OF ENDOTHELIN-RELATED DISEASESInfo
- Publication number
- AR122917A1 AR122917A1 ARP210101925A ARP210101925A AR122917A1 AR 122917 A1 AR122917 A1 AR 122917A1 AR P210101925 A ARP210101925 A AR P210101925A AR P210101925 A ARP210101925 A AR P210101925A AR 122917 A1 AR122917 A1 AR 122917A1
- Authority
- AR
- Argentina
- Prior art keywords
- zibotentan
- treatment
- combination
- dapagliflozin
- endothelin
- Prior art date
Links
- FJHHZXWJVIEFGJ-UHFFFAOYSA-N N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide Chemical compound COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=2OC=NN=2)C=C1 FJHHZXWJVIEFGJ-UHFFFAOYSA-N 0.000 title abstract 5
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title abstract 4
- 229950003684 zibotentan Drugs 0.000 title abstract 4
- 229960003834 dapagliflozin Drugs 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 3
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 2
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 2
- 102000002045 Endothelin Human genes 0.000 abstract 1
- 108050009340 Endothelin Proteins 0.000 abstract 1
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 abstract 1
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente descripción se refiere al antagonista del receptor de endotelina (ERA) zibotentan en combinación con el inhibidor de cotransportador 2 de glucosa dependiente de sodio (SGLT-2) dapagliflozina para su uso en el tratamiento de ciertas enfermedades relacionadas con endotelina. Reivindicación 1: Zibotentan, N-(3-metoxi-5-metilpirazin-2-il)-2-[4-(1,3,4-oxadiazol-2-il)fenil]piridin-3-sulfonamida, de fórmula (1), o una sal farmacéuticamente aceptable del mismo, para su uso en el tratamiento de enfermedad renal crónica en un paciente humano, administrándose zibotentan, o una sal farmacéuticamente aceptable del mismo, en combinación con dapagliflozina, (1S)-1,5-anhidro-1-{4-cloro-3-[(4-etoxifenil)metil]fenil}-D-glucitol, de fórmula (2), o una sal farmacéuticamente aceptable del mismo.The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin-related diseases. Claim 1: Zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridin-3-sulfonamide, of formula ( 1), or a pharmaceutically acceptable salt thereof, for use in the treatment of chronic kidney disease in a human patient, zibotentan, or a pharmaceutically acceptable salt thereof, being administered in combination with dapagliflozin, (1S)-1,5- anhydro-1-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-D-glucitol, of formula (2), or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063050147P | 2020-07-10 | 2020-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122917A1 true AR122917A1 (en) | 2022-10-12 |
Family
ID=83835097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101925A AR122917A1 (en) | 2020-07-10 | 2021-07-08 | ZIBOTENTAN AND DAPAGLIFLOZIN COMBINATION FOR THE TREATMENT OF ENDOTHELIN-RELATED DISEASES |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20230364077A1 (en) |
| AR (1) | AR122917A1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022009163A1 (en) * | 2020-07-10 | 2022-01-13 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
-
2021
- 2021-07-08 AR ARP210101925A patent/AR122917A1/en unknown
-
2023
- 2023-06-23 US US18/213,601 patent/US20230364077A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230364077A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2624980T3 (en) | Combination of two antivirals for the treatment of hepatitis C | |
| ES2654109T3 (en) | Combination of direct-acting antiviral agents and ribavirin to treat patients with HCV | |
| JP5232678B2 (en) | Methods for inducing cell death in neoplastic cells | |
| WO2012139028A2 (en) | Anti-viral combination therapy | |
| RU2007132181A (en) | ANTI-CANCER MEDICINE CONTAINING α, α, α-TRIFTORTIMIDINE AND A THIMIDINFOSPHORILYLASE INHIBITOR | |
| US20130171103A1 (en) | Methods for treating viral conditions | |
| CO6640268A2 (en) | Forms of oral decoding of bendamustine and its therapeutic use | |
| JP2017515908A (en) | Method for inhibiting SGLT2 inhibitor-induced glucagon secretion | |
| US20130172240A1 (en) | Methods for treating hcv | |
| JP2019214578A (en) | Methods for treating HCV | |
| CL2021003034A1 (en) | Methods of treatment of sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| CL2023000097A1 (en) | Combination of Zibotentan and Dapagliflozin for the Treatment of Chronic Kidney Disease | |
| AR122917A1 (en) | ZIBOTENTAN AND DAPAGLIFLOZIN COMBINATION FOR THE TREATMENT OF ENDOTHELIN-RELATED DISEASES | |
| AR029666A1 (en) | USE OF (+) -ALFA- (2,3-DIMETOXIFENIL) -1- [2- (4-FLUOROPHENYL) ETHYL] -4-PIPERIDINMETHANOL OR ITS DRUG FOR THE MANUFACTURE OF A MEDICINAL PRODUCT IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND OF PSYCHOSIS INDUCED BY DOPAMINE | |
| WO2016182934A1 (en) | Anti-viral compounds | |
| PE20050086A1 (en) | PHARMACEUTICAL COMBINATION INCLUDING ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT AND SODIUM BICARBONATE | |
| Chakravdhanula et al. | THERAPEUTIC HOTLINE | |
| US20200330460A1 (en) | Methods for Treating HCV | |
| BR102017022849A2 (en) | HCV TREATMENT METHODS | |
| TH100272A (en) | Remedy | |
| AR059219A1 (en) | USE OF SURAMINE FOR THE PREPARATION OF A MEDICINAL PRODUCT TO INHIBIT RETINAL AND CORNEAL NEOVASCULARIZATION |